Media
AAHI pioneers immune-enhancing platforms to provide potent, durable, broadly effective, and efficient vaccines and immunotherapies that are accessible to those who most need them.
AAHI in the News
Filter by year
Experimental COVID-19 vaccine offers long-term protection against severe disease
Successful lyophilization of a thermostable subunit tuberculosis vaccine candidate containing an emulsion-based adjuvant
What next-gen Covid-19 vaccines might look like
AAHI Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature
AAHI to Present at The 10th International mRNA Health Conference
Diversifying the Next Generation of TB Vaccines
TMA Announces the 2022 TMA Turnaround and Trasaction of the Year Awards
The Covid Gambit: Pfizer, Moderna Struggle to Get The Jump On Covid
BaiyaPhytopharm Announces Preliminary Results of the Phase 1 Clinical Trial of its COVID-19 Vaccine Baiya SARS-CoV-2 Vax 2
AAHI Contributes Its Unique Adjuvant Formulation Profiles to the National Institute of Health's Vaccine Adjuvant Compendium
Global Institute Simplifies Vaccine Manufacturing for Developing World
Two-Step QS-21 Purification Simplifies Process for Greater Use
More Durable, Broader Spectrum Boosters Needed Against COVID-19
From the fringes to the forefront - the mRNA era has taken hold of pharma
Pan-coronavirus vaccine pipeline takes form
The Access To Advanced Health Institute Receives $26 Million Donation from the Chan Soon-Shiong Family Foundation to Further Develop Immune-Enhancing Platform Technology
Released from court oversight, a Seattle research institution rebrands and resets
Infectious Disease Research Institute Exits Receivership and Launches AAHI, the Access to Advanced Health Institute, with $50 Million Funding Commitment
Featured Publication
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
A new study published recently in NPJ Vaccines describes the development of a new thermostable SARS-CoV-2 RNA vaccine by AAHI that induces potent, cross-variant humoral and cellular immune responses in preclinical rodent models. The study demonstrates that the vaccine candidate can be freeze-dried to provide stability at room temperature for six months and refrigerated temperatures for at least 10 months. The approach combines self-amplifying RNA (saRNA) with a unique stable nanostructured lipid carrier (NLC) delivery vehicle containing the adjuvant molecule squalene for optimal vaccine potency. The frozen-liquid SARS-CoV-2 RNA vaccine candidate, AAHI-SC2, is now being evaluated in Phase 1 clinical trials sponsored by ImmunityBio in South Africa, for which the vaccine candidate was well-tolerated (NCT05370040).
Read More